Apidaecin

Apidaecins enter Gram-negative bacteria through the inner membrane transporters SbmA and YjiL (same as Bac7). Once inside, they bind at the exit tunnel of the 70S ribosome with distinct contacts from other known ribosome inhibitors. Crucially, apidaecin acts as a "ribosome trapping" agent, it stalls the ribosome at the last codon before the stop codon, trapping release factors and blocking ribosome recycling. This mechanism is distinct from conventional translation inhibitors and may contribute to a lower resistance development rate.

Unlike many AMPs, apidaecins have no activity against Gram-positive bacteria or mammalian cells because they require SbmA-mediated uptake for cytoplasmic access. This transporter is present only in Gram-negative bacteria. This absolute selectivity for Gram-negatives is unusual among AMPs and provides a built-in therapeutic window against infections like E. coli, Klebsiella, and Pseudomonas without affecting beneficial Gram-positive flora or human cells.

Api88 is an 18-residue optimized analog with enhanced Gram-negative potency (MIC 0.5-4 ug/mL against E. coli, Salmonella, Shigella). Api137, with a C-terminal amide, shows improved serum stability and anti-Pseudomonas activity. In mouse peritonitis models, Api88 reduces bacterial load comparably to gentamicin. These optimized analogs represent the most advanced apidaecin-class compounds in preclinical development.

Api88 retains activity against carbapenem-resistant Klebsiella pneumoniae and ESBL-producing E. coli isolates because the ribosome-trapping mechanism is not affected by typical resistance mutations. Serial passage studies with apidaecins show resistance develops more slowly than with beta-lactams, supporting the therapeutic promise for MDR infections.